Iron deficiency (ID) is prevalent in both patients with non-dialysis chronic kidney disease (ND-CKD) and haemodialysis chronic kidney disease (HD-CKD);(1,2) however, treatment options differ between the two patient groups. Either oral or intravenous (IV) iron agents can be used to treat ID in patients with ND-CKD,(3) whereas ID in patients with HD-CKD can be treated effectively only with IV iron products.(4)
View and listen to Professor Iain C Macdougall (Professor of Clinical Nephrology at Renal Unit, King’s College Hospital, London, UK) at the ERA-EDTA 2015 Congress, where he focuses on the treatment choices for patients with ND-CKD, and explores some of the advantages and limitations associated with oral and IV iron therapy. Professor Macdougall also describes the findings of the FIND-CKD study (Ferinject assessment in patients with Iron deficiency anaemia and Non-Dialysis-dependent Chronic Kidney Disease), the largest, longest duration, randomised study comparing IV versus oral iron in patients with ND-CKD and iron deficiency-anaemia.
- Macdougall IC, Horl WH, Jacobs C, et al. European best practice guidelines 6-8: assessing and optimizing iron stores. Nephrol Dial Transplant 2000;15 Suppl 4:20–32.
- Fishbane S, Pollack S, Feldman HI, et al. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol 2009;4:57–61.
- Macdougall IC. Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous? Curr Med Res Opin 2010;26:473–482.
- Macdougall IC. Evolution of IV iron compounds over the last century. J Ren Care 2009;35 Suppl 2:8–13.